Presentation and publications
Please explain more about this section and what will be posted here...
BSI-706, Antibody-Drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors- BSI-510, a Novel Bispecific Molecule Combining an Anti-Siglec-15 Antibody with Cytokine GM-CSF for Enhanced Antitumor Efficacy
- Discovery and Development of an Anti-CD40 Agonistic Antibody for Cancer Immunotherapy
- BSI-508, a Novel Bispecific Fusion Molecule Targeting PD1 and CD47 for Cancer Immunotherapy
- BSI-507, a First-in-Class Bispecific Antibody Targeting PD1 and PVRIG for Cancer Immunotherapy
- BSI-128, a Novel Anti-HER2 Antibody Exhibiting Potent Synergistic Efficacy with TrastuzumabBSI-128isthebestfunctionalpartneroftrastuzumabidentifiedthroughtheSynAbTMplatform.BSI-128bindstoauniqueepitope,distinctfromthebindingepitopesoftrastuzumabandpertuzumab.Itexhibitssuperiorbioactivityand...
- BSI-082， a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations
- BSI-060T，a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker
COPYRIGHT © 2023.
BIOSION ALL RIGHTS RESERVED.
BIOSION ALL RIGHTS RESERVED.
Biosion USA, Inc. 591 Collaboration Way, 6th Floor Office #613, Newark, Delaware 19713, USA
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 591 Collaboration Way, 6th Floor Office #613, Newark, Delaware 19713, USA
BD@Biosion.com
1-302-998-5126
BSI-706, Antibody-Drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors- BSI-510, a Novel Bispecific Molecule Combining an Anti-Siglec-15 Antibody with Cytokine GM-CSF for Enhanced Antitumor Efficacy
- Discovery and Development of an Anti-CD40 Agonistic Antibody for Cancer Immunotherapy
- BSI-508, a Novel Bispecific Fusion Molecule Targeting PD1 and CD47 for Cancer Immunotherapy
- BSI-507, a First-in-Class Bispecific Antibody Targeting PD1 and PVRIG for Cancer Immunotherapy
- BSI-128, a Novel Anti-HER2 Antibody Exhibiting Potent Synergistic Efficacy with TrastuzumabBSI-128isthebestfunctionalpartneroftrastuzumabidentifiedthroughtheSynAbTMplatform.BSI-128bindstoauniqueepitope,distinctfromthebindingepitopesoftrastuzumabandpertuzumab.Itexhibitssuperiorbioactivityand...
- BSI-082， a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations
- BSI-060T，a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker
COPYRIGHT © 2023.
BIOSION ALL RIGHTS RESERVED.
BIOSION ALL RIGHTS RESERVED.
Biosion USA, Inc. 591 Collaboration Way, 6th Floor Office #613, Newark, Delaware 19713, USA
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 591 Collaboration Way, 6th Floor Office #613, Newark, Delaware 19713, USA
BD@Biosion.com
1-302-998-5126